Immunoglobulin Or Antibody Binds A Drug, Hapten, Hapten-carrier Complex, Or Specifically Identified Chemical Structure (e.g., Theophylline, Digoxin, Etc.) Patents (Class 435/345)
  • Patent number: 10323091
    Abstract: The instant disclosure provides antibodies that specifically bind to human PD-1 and antagonize PD-1 function. Also provided are pharmaceutical compositions comprising these antibodies, nucleic acids encoding these antibodies, expression vectors and host cells for making these antibodies, and methods of treating a subject using these antibodies.
    Type: Grant
    Filed: September 1, 2016
    Date of Patent: June 18, 2019
    Assignees: Agenus Inc., Memorial Sloan Kettering Cancer Center, Ludwig Institute for Cancer Research Ltd
    Inventors: Marc van Dijk, Nicholas Stuart Wilson, Cornelia Anne Mundt, Gerd Ritter, Jedd David Wolchok, Taha Merghoub, Roberta Zappasodi, Rikke Bæk Holmgaard, David Schaer, David Adam Savitsky
  • Patent number: 10209248
    Abstract: The present invention provides an immunoassay leading to the rapid and simultaneous detection of antibodies to a wide range of infectious pathogens in biological fluids of infected patients. This immunoassay involves the covalent and oriented coupling of fusion proteins comprising an AGT enzyme and a viral antigen on an identifiable solid support (e.g. fluorescent microspheres). The thus obtained antigen-coupled microspheres show enhanced capture of specific antibodies as compared to antigen-coupled microspheres produced by standard amine coupling procedures.
    Type: Grant
    Filed: July 19, 2017
    Date of Patent: February 19, 2019
    Assignee: Institut Pasteur
    Inventors: Jean-Claude Manuguerra, Jessica Vanhomwegen, Philippe Despres, Sylvie Paulous
  • Patent number: 9512212
    Abstract: The present invention relates to therapeutic agents comprising bispecific recombinant antibody fragments to selectively clear a protein associated with a neurological disease and methods of use of these therapeutic agents to treat neurological diseases.
    Type: Grant
    Filed: January 10, 2013
    Date of Patent: December 6, 2016
    Assignee: Arizona Board of Regents, a Body Corporate of the State of Arizona, Acting for and on Behalf of Arizona State University
    Inventors: Michael Sierks, Yong Shen
  • Patent number: 9458246
    Abstract: Described herein are bispecific proteins specific for BAFF and B7RP1, nucleic acids encoding such proteins, methods of making such proteins, and uses for such proteins.
    Type: Grant
    Filed: March 10, 2014
    Date of Patent: October 4, 2016
    Assignee: AMGEN INC.
    Inventors: Hailing Hsu, Ming Zhang, Gunasekaran Kannan, Frederick W. Jacobsen, Wayne Tsuji
  • Patent number: 9169330
    Abstract: The present invention relates to a hybridoma producing an anti-methylated DNA antibody, obtained by cell fusion of an antibody-producing cell obtained from an animal immunized with an antigen containing 5?-(5-methyl-2?-deoxycytidine-3?-phospho)-2?-deoxyguanosine 3?-phosphate with a myeloma cell. The present invention also relates to a monoclonal antibody produced by the hybridoma and a method for immunoprecipitation of a methylated DNA using the antibody.
    Type: Grant
    Filed: March 26, 2012
    Date of Patent: October 27, 2015
    Assignee: SYSMEX CORPORATION
    Inventors: Ayako Sakai, Masahiro Kajita
  • Publication number: 20150072368
    Abstract: Novel transcription units that may be used in expression vectors. The transcription unit allow antibodies to be produced whose gain in productivity is not linked to a particular antigenic target antibody and therefore by extrapolation to a given recombinant protein, nor linked to the culture medium.
    Type: Application
    Filed: February 8, 2013
    Publication date: March 12, 2015
    Applicant: LABORATOIRE FRANCAIS DU FRACTIONNEMENT ET DES BIOTECHNOLOGIES
    Inventors: Alexandre Fontayne, François Coutard
  • Publication number: 20150044236
    Abstract: Disclosed is an isolated antigen binding protein, such as but not limited to, an antibody or antibody fragment. Also disclosed are pharmaceutical compositions and medicaments comprising the antigen binding protein, isolated nucleic acid encoding it, vectors, host cells, and hybridomas useful in methods of making it. In some embodiments the antigen binding protein comprises one to twenty-four pharmacologically active chemical moieties conjugated thereto, such as a pharmacologically active polypeptide.
    Type: Application
    Filed: May 22, 2014
    Publication date: February 12, 2015
    Applicant: AMGEN INC.
    Inventors: Kenneth W. WALKER, Yue-Sheng LI, Thomas Charles BOONE, HoSung MIN, Jane TALVENHEIMO, Taruna ARORA, Frederick W. JACOBSEN
  • Publication number: 20150044235
    Abstract: Disclosed is an isolated antigen binding protein, such as but not limited to, an antibody or antibody fragment. Also disclosed are pharmaceutical compositions and medicaments comprising the antigen binding protein, isolated nucleic acid encoding it, vectors, host cells, and hybridomas useful in methods of making it. In some embodiments the antigen binding protein comprises one to twenty-four pharmacologically active chemical moieties conjugated thereto, such as a pharmacologically active polypeptide.
    Type: Application
    Filed: May 22, 2014
    Publication date: February 12, 2015
    Applicant: Amgen Inc.
    Inventors: Kenneth W. WALKER, Yue-Sheng LI, Thomas Charles BOONE, George DOELLGAST (DECEASED), HoSung MIN, Jane TALVENHEIMO, Taruna ARORA, Frederick W. JACOBSEN
  • Patent number: 8946167
    Abstract: The invention is related to water-soluble products and pharmaceutical formulations in solid or liquid form mainly for parenteral use. They consist of or comprise a therapeutically active substance (having low aqueous solubility and a substantial binding affinity to plasma proteins) and a plasma protein fraction in controlled aggregation state, whereby the said active substance and the said protein fraction are bound to each other by way of non-covalent bonds. It also covers processes for the preparation of the product and pharmaceutical formulation by dissolving the water-insoluble active substance in a water-miscible, pharmaceutically acceptable solvent, combining said solution with the aqueous solution of a plasma protein fraction in controlled aggregation state whereby a true solution is obtained containing the said active substance and the said protein fraction bound together by way of non-covalent bonds.
    Type: Grant
    Filed: February 9, 2009
    Date of Patent: February 3, 2015
    Assignee: Teva Pharmaceutical Industries Ltd.
    Inventors: Lajos Hegedus, Krisztina Krempels, Krisztina Paal, Gabor Petho
  • Publication number: 20140349319
    Abstract: The present invention provides a method of detecting or measuring trans-Resveratrol (tRV) in a sample, comprising: contacting a sample to be tested with an antibody against tRV, or an antigen binding fragment of such an antibody; and detecting or measuring any tRV bound by the antibody or antibody fragment. The invention also provides an antibody against trans-Resveratrol.
    Type: Application
    Filed: November 9, 2012
    Publication date: November 27, 2014
    Inventors: Ivan Petyaev, Valery Tsybezov
  • Publication number: 20140336156
    Abstract: Provided herein are antigenic molecules that can be used to generate antibodies capable of binding to a vitamin D derivative, such as 25-hydroxyvitamin D2 and/or 25-hydroxyvitamin D3, or a 25-hydroxyvitamin D analog, such as a vitamin D-C22 immunogenic molecule or compound. Antibodies produced using these antigenic molecules, and related antigenic compounds, are also described. In addition, disclosed herein are methods for detecting vitamin D deficiency in a subject, methods for treating a subject suspected of having a vitamin D deficiency, methods for monitoring progression of vitamin D deficiency in a subject, and methods for monitoring treatment of vitamin D deficiency in a subject in need thereof. The methods involve the detection or quantification of 25-hydroxyvitamin D2 and D3.
    Type: Application
    Filed: July 18, 2014
    Publication date: November 13, 2014
    Inventors: NIVER PANOSIAN SAHAKIAN, Bruce A. Campbell, Spencer Hsiang-Hsi Lin, JAMES Vincent FREEMAN, Qimu Liao, RAMON A. EVANGELISTA
  • Publication number: 20140314832
    Abstract: The present invention relates to pharmaceutical and medical technologies, and more particularly to novel nanobodies against pulmonary surfactant protein A (SP-A) and their preparation methods. The nanobodies of the present invention comprises an amino acid sequence having certain formula. The present invention also relates to nucleic acid sequences encoding the nanobodies, their preparation method and their applications. Immunohistochemistry and in vivo imaging show that the nanobodies of the present inventions have high lung-targeting specificity.
    Type: Application
    Filed: August 2, 2013
    Publication date: October 23, 2014
    Applicant: Shanghai Pulmonary Hospital, Tongji University School of Medicine
    Inventors: Huiping Li, Shanmei Wang
  • Patent number: 8846391
    Abstract: The invention provides methods for sensitive and specific detection of anti-HSV-2 antibodies by depletion of cross-reactive (non-specific) antibodies in a biological sample that can lead to a false positive result. The invention also features compositions, including nucleic acids, polypeptides, and kits, for use in the methods of the invention.
    Type: Grant
    Filed: June 23, 2010
    Date of Patent: September 30, 2014
    Assignee: Focus Diagnostics, Inc.
    Inventors: Xin Su, Lilly Kong, Wayne Hogrefe
  • Publication number: 20140271688
    Abstract: The present invention relates to anti-cKIT antibodies, antibody fragments, antibody drug conjugates, and their uses for the treatment of cancer.
    Type: Application
    Filed: March 12, 2014
    Publication date: September 18, 2014
    Applicants: IRM LLC, NOVARTIS AG
    Inventors: Tinya Abrams, Steven Bruce Cohen, Christie P. Fanton, Thomas Huber, Kathy Miller, Siew Ho Schleyer, Kathrin Ulrike Tissot-Daguette, Catrin Finner
  • Publication number: 20140193413
    Abstract: The present disclosure relates to an antibody or antibody fragment capable of binding to phosphorylcholine and/or a phosphorylcholine conjugate, wherein the antibody or antibody fragment comprises a variable heavy chain (VH) domain and/or a variable light chain (VL) domain, and wherein (a) the VH domain comprises complementarity determining regions (CDRs) selected from the group consisting of: a CDR1 sequence having identity to the sequence of SEQ ID NO: 7; a CDR2 sequence having identity to the sequence of SEQ ID NO: 8; and a CDR3 sequence having identity to the sequence of SEQ ID NO: 9 or 10; and/or (b) the VL domain comprises CDRs selected from the group consisting of: a CDR4 sequence having identity to the sequence of SEQ ID NO: 11; a CDR5 sequence having identity to the sequence of SEQ ID NO: 12; a CDR6 sequence having identity to the sequence of SEQ ID NO: 13.
    Type: Application
    Filed: August 8, 2012
    Publication date: July 10, 2014
    Applicants: DYAX CORP., ATHERA BIOTECHNOLOGIES AB
    Inventors: Knut Pettersson, Ola Camber, Dan Sexton, Andrew E. Nixon
  • Publication number: 20140186377
    Abstract: The present invention encompasses prostaglandin E2 (PGE2) binding proteins. The invention relates to antibodies that are wild-type, chimeric, CDR grafted and humanized. Preferred antibodies have high affinity for prostaglandin E2 and neutralize prostaglandin E2 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody, or an antigen-binding portion thereof. Methods of making and methods of using the antibodies of the invention are also provided. The antibodies, or antigen-binding portions, of the invention are useful for detecting prostaglandin E2 and for inhibiting prostaglandin E2 activity, e.g., in a human subject suffering from a disorder in which prostaglandin E2 activity is detrimental.
    Type: Application
    Filed: November 26, 2013
    Publication date: July 3, 2014
    Applicant: AbbVie, Inc.
    Inventors: Jijie Gu, Charles W. Hutchins, Rong-Rong Zhu, Jianwei Shen, Maria C. Harris, Eileen Belanger, Tariq Ghayur, Paul R. Hinton, Veronica M. Juan, John Mankovich, Junjian Liu
  • Publication number: 20140178410
    Abstract: The present invention relates to an antibody or antibody fragment capable of binding to phosphorylcholine and/or a phosphorylcholine conjugate, wherein the antibody or antibody fragment comprises a variable heavy chain (VH) domain and/or a variable light chain (VL) domain, and wherein—(a) the VH domain comprises an amino acid sequence that includes one, two or three complementarity determining regions (CDRs) selected from the group consisting of: a CDR1 sequence comprising an amino acid sequence having at least 25%, 50%, 75% or 100% sequence identity to the sequence of SEQ ID NO: 17; a CDR2 sequence comprising an amino acid sequence having at least 5%, 11%, 17%, 23%, 29%, 35%, 47%, 52%, 58%, 64%, 70%, 76%, 82%, 94% or 100% sequence identity to the sequence of SEQ ID NO: 18; and a CDR3 sequence comprising an amino acid sequence having at least 4%, 9%, 13%, 18%, 22%, 27%, 31%, 36%, 40%, 45%, 50%, 54%, 59%, 63%, 68%, 72%, 77%, 81%, 86%, 90%, 95% or 100% sequence identity to the sequence of SEQ ID NO: 19, 20, 21
    Type: Application
    Filed: August 8, 2012
    Publication date: June 26, 2014
    Applicants: DYAX CORP., ATHERA BIOTECHNOLOGIES AB
    Inventors: Knut Pettersson, Ola Camber, Dan Sexton, Andrew E. Nixon
  • Publication number: 20140093915
    Abstract: Provided herein are IL-18 receptor antigen binding proteins and polynucleotides encoding the same. Expression vectors and host cells comprising the same for production of the antigen binding proteins are also provided. In addition, provided are compositions and methods for diagnosing and treating diseases mediated by IL-18 receptor.
    Type: Application
    Filed: September 3, 2013
    Publication date: April 3, 2014
    Applicant: AMGEN INC.
    Inventors: DIRK E. SMITH, JOHN E. SIMS, JEFFREY T. MCGREW, MAREK Z. KUBIN, DUNCAN COCHRANE, LOUISE CONROY
  • Publication number: 20140050743
    Abstract: The present invention relates to the identification and use of antigen-binding regions, antibodies, antigen-binding antibody fragments and antibody mimetics, neutralizing the anti-coagulant effect of an anticoagulant in vitro and/or in vivo. Antibodies and functional fragments of the invention and antibody mimetics can be used to specifically reverse the pharmacological effect of an anticoagulant e.g. a FXa inhibitor for therapeutic (antidote) and/or diagnostic purposes. The invention also provides nucleic acid sequences encoding foregoing molecules, vectors containing the same, pharmaceutical compositions and kits with instructions for use.
    Type: Application
    Filed: January 17, 2012
    Publication date: February 20, 2014
    Applicant: BAYER INTELLECTUAL PROPERTY GMBH
    Inventors: Frank Dittmer, Anja Buchmüller, Christoph Gerdes, Adrian Tersteegen, Mark Jean Gnoth, Lars Linden, Axel Harrenga, Joanna Grudzinska-Goebel, Mario Jeske, Martina Schäfer, Jörg Birkenfeld, Holger Paulsen, Ricarda Finnern, Anke Mayer-Bartschmid, Andrea Eicker, Simone Greven, Susanne Steinig
  • Publication number: 20140044739
    Abstract: The present disclosure relates to Cell Death Inducing Molecule (“CDIM”) binding proteins and pharmaceutical compositions thereof. Particularly, the disclosure provides CDIM binding proteins that are useful in the selective depleting and killing of B cells, including neoplastic B cells as well as neoplastic cells that are not of B-cell origin that express CDIM-like antigens. In addition, the disclosure encompasses polynucleotides encoding the disclosed antigen binding proteins, and expression systems for producing the same. Further the present disclosure encompasses methods of treating patients with B cell proliferative- and mediated diseases by administering the CDIM binding proteins as well as diagnostic assays for identifying proteins that bind to CDIM. The disclosure further contemplates diagnostic assays for identifying patient populations that can be treated with the CDIM binding proteins.
    Type: Application
    Filed: February 8, 2013
    Publication date: February 13, 2014
    Inventors: Nelson N. H. Teng, Neelima M. Bhat, Marcia M. Bieber, Bruce A. Keyt
  • Publication number: 20140030271
    Abstract: The present invention concerns monoclonal antibodies specifically binding the human HMGB1 protein and further HMGB1 proteins of mammalian origin and also concerns fragments thereof, nucleic acids encoding such antibodies or fragments thereof, as well as vectors, cells, and compositions comprising the antibodies or nucleic acids, and uses thereof.
    Type: Application
    Filed: April 5, 2011
    Publication date: January 30, 2014
    Applicant: DIA.PRO DIAGNOSTIC BIOPROBES S.R.L.
    Inventor: Cristina Scozzesi
  • Publication number: 20130317201
    Abstract: It is an object of the present invention to provide an anti-cadherin antibody having a high internalization capacity and provide an anti-cadherin antibody-drug conjugate that effectively kills cadherin-expressing cancer cells with the use of such antibody. The present invention provides an anti-cadherin antibody which recognizes a cadherin domain 1 (EC1) of cadherin and exhibits a high internalization capacity.
    Type: Application
    Filed: October 28, 2011
    Publication date: November 28, 2013
    Applicant: PERSEUS PROTEOMICS INC.
    Inventors: Keisuke Ishii, Keiko Katsumi, Tadashi Matsuura, Yukio Sudo, Katsuyuki Mitomo, Katsushi Kouda
  • Publication number: 20130295095
    Abstract: The invention relates to binding molecules capable of specifically recognizing soluble oligomers of N-terminal truncated A? starting with pyroglutamate (A??E), pharmaceutical compositions comprising same, and their respective therapeutic uses. Particularly, the invention relates to an antibody molecule capable of specifically recognizing A? oligomers, wherein said antibody binds and/or detects an epitope as bound and/or detected by antibody PG3-38 9D5H6 as deposited under DSM AC-C3056.
    Type: Application
    Filed: June 3, 2011
    Publication date: November 7, 2013
    Inventors: Thomas Bayer, Oliver Wirths, Henrik Martens, Christian Erck
  • Publication number: 20130287799
    Abstract: The subject invention relates to monoclonal antibodies that may be used in the treatment and diagnosis of Alzheimer's Disease. In particular, the present invention relates to monoclonal antibodies referred to as 10F4 and 3C5 and to other monoclonal antibodies (e.g., murine, human or humanized) having similar properties thereto.
    Type: Application
    Filed: April 15, 2013
    Publication date: October 31, 2013
    Inventors: Abbott Laboratories, Abbott GmbH & Co. KG
  • Patent number: 8507214
    Abstract: The present invention provides an ELISA kit for detecting lincomycin comprising a coating antigen and an enzyme labeled reagent, wherein the coating antigen is selected from the group consisting of a lincomycin hapten-carrier protein conjugate, a lincomycin antibody and a lincomycin anti-antibody; when the coating antigen is the lincomycin hapten-carrier protein conjugate, the enzyme labeled reagent is an enzyme-labeled lincomycin anti-antibody; when the coating antigen is the lincomycin antibody, the enzyme labeled reagent is an enzyme-labeled lincomycin hapten-carrier protein conjugate; and when the coating antigen is the lincomycin anti-antibody, the enzyme labeled reagent is an enzyme-labeled lincomycin hapten-carrier protein conjugate; and the lincomycin hapten is obtained through the condensation reaction between lincomycin and succinic anhydride.
    Type: Grant
    Filed: September 27, 2008
    Date of Patent: August 13, 2013
    Assignee: Beijing Kwinbon Biotechnology Co., Ltd.
    Inventors: Fangyang He, Yuping Wan, Caiwei Feng, Zhengmiao Zhao, Caimao Feng, Shanliang Wang, Xiaoqin Luo, Xiaobin Ma
  • Publication number: 20130195872
    Abstract: This invention provides fully human monoclonal antibodies that recognize IL-17F, the IL-17F homodimer, IL-17A, the IL-17A homodimer, and/or the heterodimeric IL-17A/IL-17F protein complex. The invention further provides methods of using such monoclonal antibodies as a therapeutic, diagnostic, and prophylactic.
    Type: Application
    Filed: March 14, 2013
    Publication date: August 1, 2013
    Applicant: NOVIMMUNE S.A.
    Inventor: NOVIMMUNE S.A.
  • Publication number: 20130189283
    Abstract: Disclosed is an isolated immunoglobulin. Also disclosed are pharmaceutical compositions and medicaments comprising the immunoglobulin, isolated nucleic acid encoding it, vectors, host cells, useful in methods of making it. In some embodiments the immunoglobulin comprises one to twenty-four pharmacologically active chemical moieties conjugated thereto, such as a pharmacologically active polypeptide.
    Type: Application
    Filed: September 22, 2011
    Publication date: July 25, 2013
    Applicant: AMGEN INC.
    Inventors: Kenneth W. Walker, Frederick W. Jacobsen, Taruna Arora
  • Patent number: 8491907
    Abstract: The invention described herein provides for human antibodies produced in non-human animals that specifically bind to lipopolysaccharide (LPS) from strains Fisher Devlin (International Serogroups) It-2 (011), It-3 (02), It-4 (01), It-5 (010), It-6 (07), PA01 (05), 170003 (02), IATS016 (02/05), and 170006 (02). The invention further provides methods for making the antibodies in a non-human animal, expression of the antibodies in cell lines including hybridomas and recombinant host cell systems. Also provided are kits and pharmaceutical compositions comprising the antibodies and methods of treating or preventing pseudomonas infection by administering to a patient the pharmaceutical compositions described herein.
    Type: Grant
    Filed: July 13, 2010
    Date of Patent: July 23, 2013
    Assignee: Amgen, Inc.
    Inventor: John R. Schreiber
  • Patent number: 8435784
    Abstract: A method of preserving haptenized tumor cells is described. The method employs a freezing medium containing an effective amount of sucrose and human serum albumin in an isotonic buffered saline solution. Cryogenically preserving haptenized cells in such a medium has been found to maintain the integrity of the tumor cells during storage. The haptenized tumor cells also retain cell-associated antigens and haptens, and are as immunogenic, i.e., capable of inducing immunotherapeutic response, as fresh vaccine in a mouse model of metastatic disease. In a specific embodiment, haptenized cells are exposed to a solution of 8% sucrose, 10% human serum albumin in Hank's buffered solution, and then frozen to ?80° C. overnight and then stored in a liquid nitrogen freezer. Methods of storing haptenized tumor cells and compositions are also provided.
    Type: Grant
    Filed: June 13, 2007
    Date of Patent: May 7, 2013
    Inventors: David Berd, Lorne F. Erdile, Margalit B. Mokyr
  • Publication number: 20130108644
    Abstract: Compositions and methods are provided for alleviating cancer in a mammal by administering a therapeutic dose of a pharmaceutical composition that inhibits activity of AXL protein activity, for example by competitive or non-competitive inhibition of the binding interaction between AXL and its ligand GAS6.
    Type: Application
    Filed: August 27, 2012
    Publication date: May 2, 2013
    Inventors: Amato J. Giaccia, Erinn Bruno Rankin, Jennifer R. Cochran, Douglas Jones, Mihalis Kariolis, Katherine Fuh, Yu Miao
  • Publication number: 20130059825
    Abstract: Provided herein are antigenic molecules that can be used to generate antibodies capable of binding to a vitamin D derivative, such as 25-hydroxyvitamin D2 and/or 25-hydroxyvitamin D3, or a 25-hydroxyvitamin D analog, such as a vitamin D-C22 immunogenic molecule or compound. Antibodies produced using these antigenic molecules, and related antigenic compounds, are also described. In addition, disclosed herein are methods for detecting vitamin D deficiency in a subject, methods for treating a subject suspected of having a vitamin D deficiency, methods for monitoring progression of vitamin D deficiency in a subject, and methods for monitoring treatment of vitamin D deficiency in a subject in need thereof. Also provided are methods and reagents for the detection or quantification of 25-hydroxyvitamin D2 and D3, methods for stabilizing vitamin D analogs, and methods for separating 25-hydroxyvitamin D2 and D3 from vitamin D binding protein in a biological sample.
    Type: Application
    Filed: April 27, 2012
    Publication date: March 7, 2013
    Applicant: Siemens Healthcare Diagnostics Inc.
    Inventors: Niver Panosian Sahakian, Bruce A. Campbell, Spencer Hsiang-Hsi Lin, James Vincent Freeman, Qimu Liao, Ramon A. Evangelista
  • Publication number: 20120100158
    Abstract: A hybridoma cell which has been deposited under ATCC Accession Number PTA-9974 is disclosed. Also provided are Antibodies and methods of using same.
    Type: Application
    Filed: April 29, 2010
    Publication date: April 26, 2012
    Applicant: RAMOT AT TEL AVIV UNIVERSITY LTD.
    Inventors: Gal Markel, Rona Ortenberg
  • Patent number: 8153767
    Abstract: It is intended to detect, concentrate and purify aflatoxins of all types which are possibly contained in a sample such as a food. It is also intended to detect the total amount or the individual amounts thereof at a high sensitivity. By using aflatoxin B2 or its derivative as a hapten compound, an antibody, which shows the same reactivity to individual aflatoxin analogs and is highly tolerant to organic solvents, is obtained. Then, a detection/concentration/purification means and an immunological detection means with the use of the above antibody are constructed. The detection means thus constructed achieves a high sensitivity and excellent quantification properties.
    Type: Grant
    Filed: November 13, 2007
    Date of Patent: April 10, 2012
    Assignee: HORIBA, Ltd.
    Inventors: Mikiko Uchigashima, Shiro Miyake, Hiroshi Yamashita
  • Patent number: 8148059
    Abstract: A method of detecting malignancy of nasopharyngeal carcinoma and a nasopharyngeal carcinoma malignancy biomarker are disclosed. Firstly, a specimen is obtained from a testee. Next, the specimen is tested for its MIP-3? expression level. Then, the MIP-3? expression level of the specimen is compared with that of a control. Finally, the malignancy of nasopharyngeal carcinoma is determined according to a relative MIP-3? expression level between the specimen and the control.
    Type: Grant
    Filed: October 30, 2009
    Date of Patent: April 3, 2012
    Assignee: Chang Gung University
    Inventors: Jau-Song Yu, Kai-Ping Chang
  • Publication number: 20120045443
    Abstract: The invention concerns agonist anti-trkC monoclonal antibodies which mimic certain biological activities of NT-3, the native ligand of trkC. The invention further concerns the use of such antibodies in the prevention and/or treatment of cellular degeneration, including nerve cell damage associated with acute nervous cell system injury and chronic neurodegenerative diseases, including peripheral neuropathy.
    Type: Application
    Filed: August 5, 2011
    Publication date: February 23, 2012
    Inventors: Brigitte Devaux, Jo-Anne Hongo, Leonard G. Presta, David L. Shelton
  • Publication number: 20120027782
    Abstract: The present disclosure relates to antibody-partner molecule conjugates directed to PTK7. Also described are methods for treating or preventing a disease characterized by growth of tumor cells expressing PTK7 using the antibody-partner molecule conjugates.
    Type: Application
    Filed: November 26, 2008
    Publication date: February 2, 2012
    Applicant: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Jonathan Alexander Terrett, Chin Pan, Chetana Rao-Naik
  • Publication number: 20120015380
    Abstract: In this invention, anti-PEG antibodies or anti-methoxyl-PEG (anti-CH3O-PEG) antibodies were expressed on cell surface which can collocate with a biotinylated anti-PEG antibody (AGP4-Biotin) or biotinylated PEG (PEG-Biotin) to develop a cell-based sandwich ELISA or a cell-based competition ELISA, respectively. Both of these two methods could sensitively quantify free PEG and PEG-modified macromolecules (proteins, nanoparticles and liposomes) as sensitive as nano-gram level.
    Type: Application
    Filed: February 22, 2011
    Publication date: January 19, 2012
    Applicant: KAOHSIUNG MEDICAL UNIVERSITY
    Inventors: Tian-Lu Cheng, Steven R. Roffler, Kuo-Hsiang Chuang, Ssu-Jung Lu
  • Publication number: 20110305715
    Abstract: The invention provides antibodies, and antigen-binding fragments thereof, that specifically bind to 3-hydroxycotinine (3HC). The invention also provides compositions containing these antibodies and fragments thereof, and to their use in diagnostic and therapeutic applications for diseases involving nicotine activity (e.g., smoking and/or smokeless tobacco use).
    Type: Application
    Filed: June 10, 2011
    Publication date: December 15, 2011
    Inventors: Lynn Y. Miao, Jennifer G. Johnson, Adriana Navarro, Paul Olivo, David Scholl
  • Publication number: 20110280884
    Abstract: A human antibody or a functional fragment thereof having specific binding ability to CD98 which is derived from the cell membrane of cancer cells and is in the form of a complex with a protein having an amino acid transporter activity (for example, LAT1) is disclosed. This antibody binds to CD98 in the form of a dimer with LAT1 on the surface of cancer cells, specifically attacks cancer cells expressing CD98 via the immune system by ADCC or CDC, and further inhibits amino acid uptake of the cancer cells via LAT1, to suppress growth of the cancer cells. Accordingly, a preventive and therapeutic agent for cancer comprising this antibody or a fragment thereof, which acts on various cancers, is specific to cancer, and causes no side effect, is provided.
    Type: Application
    Filed: May 12, 2011
    Publication date: November 17, 2011
    Inventors: Tomoyuki TAHARA, Yoshikatsu Kanai, Hitoshi Endou, Shiro Kataoka, Kazumasa Hasegawa, Tetsuya Yoshino
  • Patent number: 8048676
    Abstract: The invention provides reagents and methods for detecting pathogen infections in human samples. This detection utilizes specific proteins to detect the presence of pathogen proteins or abnormal expression of human proteins resulting from pathogen infections. Specific methods, compositions and kits are disclosed herein for the detection of oncogenic Human papillomavirus E6 proteins in clinical samples.
    Type: Grant
    Filed: January 5, 2007
    Date of Patent: November 1, 2011
    Assignee: Arbor Vita Corporation
    Inventors: Peter S. Lu, Johannes Schweizer, Chamorro Somoza Diaz-Sarmiento, Michael P. Belmares
  • Patent number: 8039599
    Abstract: Monoclonal antibodies to rapamycin and to 40-O-alkylated derivatives of rapamycin are provided, together with novel haptens, immunogenic conjugates, and processes for making them and assay kits for using them.
    Type: Grant
    Filed: June 2, 2000
    Date of Patent: October 18, 2011
    Assignee: Novartis AG
    Inventors: Richard Sedrani, Valerie Quesniaux
  • Patent number: 8021849
    Abstract: Methods and kits for determining sirolimus in a sample known or suspected to contain sirolimus are provided. The methods and kits according to the invention use one or more antibodies generated using a fragment of sirolimus, such as the northern fragment of sirolimus.
    Type: Grant
    Filed: November 5, 2004
    Date of Patent: September 20, 2011
    Assignee: Siemens Healthcare Diagnostics Inc.
    Inventor: Michael S. Huster
  • Publication number: 20110223684
    Abstract: Methods are described for improving the diagnostic possibilities of diseases where oxidative NO-modifications occur, for example inflammatory conditions, cancer, Parkinson's or Alzheimer's disease, and to provide means of monitoring the effects of therapeutical measures taken towards such diseases. The invention enables the detection of disease specific catabolic markers related to oxidative NO-modifications, utilizing an immunoassay comprising antibodies directed against nitrated and non-nitrated epitopes characteristic of a specific protein.
    Type: Application
    Filed: January 20, 2011
    Publication date: September 15, 2011
    Inventors: Jean-Yves Reginster, Michelle Deberg, Yves Henrotin, Stephan Christgau
  • Patent number: 8008001
    Abstract: The present invention relates to a vaccine and a method for protecting piglets against PCV-2 infection by administering a vaccine comprising at least 20 micrograms/dose of ORF-2 protein of porcine circovirus type 2, even when they have a relatively high titer of maternally derived antibodies against PCV-2. A vaccine according to the invention may contain a recombinant ORF-2 protein, wherein said recombinant protein is preferably produced by way of expression from a baculovirus expression vector in insect cells, said baculovirus expression vector containing the PCV-2 ORF-2 gene sequence under control of a suitable promoter.
    Type: Grant
    Filed: December 11, 2009
    Date of Patent: August 30, 2011
    Assignee: Intervet International B.V.
    Inventors: Frank Roerink, Peter Van Woensel
  • Patent number: 7943343
    Abstract: The present invention relates to a bi-specific antibody or antibody fragment having at least one arm that is reactive against a targeted tissue and at least one other arm that is reactive against a targetable conjugate. The targetable conjugate encompasses a hapten to which antibodies have been prepared. In preferred embodiments, the hapten is histamine-succinyl-glycine (HSG). In more preferred embodiments, the at least one arm comprises the CDR sequences of the HSG-binding 679 antibody. The targetable conjugate is attached to one or more therapeutic and/or diagnostic agents. The invention provides constructs and methods for producing the bispecific antibodies or antibody fragments, as well as methods for using them and kits comprising them.
    Type: Grant
    Filed: October 20, 2009
    Date of Patent: May 17, 2011
    Assignee: Immunomedics, Inc.
    Inventors: Hans J. Hansen, Gary L. Griffiths, Shui-on Leung, William J. McBride, Zhengxing Qu
  • Patent number: 7910310
    Abstract: This invention relates to the relationship between infection with an adipogenic adenovirus, such as adenovirus-36, and obesity-related disease. In particular, this invention relates to assaying a subject to determine the adipogenic adenovirus infection status and then determining the subject's predisposition to developing an obesity-related disease based on the adipogenic adenovirus infection status.
    Type: Grant
    Filed: October 24, 2008
    Date of Patent: March 22, 2011
    Assignee: Obetech, LLC
    Inventor: Richard L. Atkinson
  • Publication number: 20110052608
    Abstract: The present invention relates to a novel antibody which selectively binds to the disease associated form of prion protein (PrPSc) under native conditions and the use thereof in methods of prion disease detection, therapy and disease research in general.
    Type: Application
    Filed: June 13, 2007
    Publication date: March 3, 2011
    Applicant: UNIVERSITY COURT OF THE UNIVERSITY OF EDINBURGH
    Inventors: Mark William Head, Michael Jones
  • Patent number: 7897733
    Abstract: Provided are rapamycin conjugates which are useful as immunogenic molecules for the generation of antibodies specific for rapamycin, for measuring levels of rapamycin or derivatives thereof; for isolating rapamycin binding proteins; and detecting antibodies specific for rapamycin or derivatives thereof. This invention also provides a rapamycin specific monoclonal antibody.
    Type: Grant
    Filed: November 14, 2005
    Date of Patent: March 1, 2011
    Assignee: Pfizer, Inc.
    Inventors: Katherine L. Molnar-Kimber, Craig E. Caufield, Timothy D. Ocain
  • Publication number: 20110020219
    Abstract: A novel anti-human tenascin ST2146 monoclonal antibody is described endowed with high affinity with the native antigen and high tumor selectivity. The cST2146 hybridoma is stably producing the antibody in high density culture conditions and is suitable for the industrial development of ST2146-based products. ST2146 exhibits properties exploitable for both therapeutic and diagnostic applications.
    Type: Application
    Filed: September 17, 2008
    Publication date: January 27, 2011
    Applicant: SIGMA-TAU INDUSTRIE FARMACEUTICHE
    Inventors: De Santis Rita, Anastasi Anna Maria
  • Publication number: 20110014656
    Abstract: Disclosed are antagonists of IL-17A and IL-17F. The antagonists are based on soluble IL-17RA and IL-17RC fusion proteins, including hybrid soluble receptors comprising portions of both IL-17RC and IL-17RA (“IL-17RC/IL-17RA”). Such antagonists serve to block, inhibit, reduce, antagonize or neutralize the activity of IL-17F, IL-17A, or both IL-17A and IL-17F. Also disclosed are methods of using such antagonists for treating disease, particularly inflammatory diseases mediated at least in part by IL-17A and/or IL-17F.
    Type: Application
    Filed: June 30, 2010
    Publication date: January 20, 2011
    Applicant: ZYMOGENETICS, INC.
    Inventors: STEVEN D. LEVIN, MARK W. RIXON, GAO ZEREN